Latest:
Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC
Dr Lisberg discusses key findings from the TROPION-Lung01 trial of Dato-DXd in patients with previously treated advanced or metastatic NSCLC.
Authors
Sophie Paczesny, MD, PhD
Sophie Paczesny MD, PhD, is a professor in the Department of Microbiology and Immunology and co-leader of the Cancer Immunology Program at the Hollings Cancer Center at the Medical University of South Carolina.
Latest:
Dr Paczesny on ST2 as a Biomarker for Acute GVHD Risk Post-Transplant
Sophie Paczesny MD, PhD, discussed the ability of ST2 to predict the risk of developing aGVHD or death following transplant.
Susan Scott, MD
Susan Scott, MD, is a thoracic medical oncologist, at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; as well as assistant professor of oncology at the Johns Hopkins University School of Medicine
Latest:
Lung Cancer Experts Highlight the Significance and Limitations of ADCs
Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.
Yufei Liu, MD, PhD
Yufei Liu, MD, PhD, is an assistant clinical professor in the Department of Radiation Oncology at City of Hope in Duarte, California.
Latest:
Dr Liu on SBRT and IMRT in Colorectal Cancer
Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.
Melinda L. Telli, MD
Latest:
Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer
Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.
Marina Frimer, MD, FACOG, FACS
Latest:
Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma
Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma
Horacio J. Asbun, MD
Latest:
Mapping Progress in Pancreatic Cancer Surgery: Leveraging New Technology
In this last episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, explain how augmented reality or artificial intelligence may be utilized to improve outcomes for patients with pancreatic cancer who are undergoing surgical procedures.
Jacqueline Aredo, MD, MS
Latest:
Dr Aredo on the Molecular Distribution of Screening-Eligible Patients With NSCLC
Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.